2023 World Conference on Lung Cancer (Posters)-P1.01. A Phase IB Trial Of Nivolumab For Immunoprevention Of Bronchial Dysplasia Progression In High-risk Current And Former Smokers

P1.01. A Phase IB Trial Of Nivolumab For Immunoprevention Of Bronchial Dysplasia Progression In High-risk Current And Former Smokers - PDF(Abstract)

Back to course

Pdf Summary

This document is a summary of a presentation titled "A Phase IB Trial Of Nivolumab For Immunoprevention Of Bronchial Dysplasia Progression In High-risk Current And Former Smokers" at the WCLC 2023 conference. The study investigates the efficacy of using the drug nivolumab to prevent the progression of bronchial dysplasia in high-risk smokers. Bronchial dysplasias can lead to lung squamous cell carcinoma, and immune checkpoint inhibitors have been successful in treating lung cancer, so the study aims to determine if nivolumab can prevent dysplasia progression. The methods of the study include administering four doses of nivolumab to eligible subjects and performing bronchoscopy at the conclusion of treatment and after six months. The primary endpoints are improvement in histologic score and safety, and secondary endpoints include correlating immune microenvironment alterations and mutational load with response to nivolumab. So far, 16 subjects have completed the treatment, and nine of them showed histologic improvement. The study also found that certain immune cells and molecules were different in responders compared to non-responders, suggesting a correlation between these factors and response to nivolumab. The conclusion is that nivolumab is well tolerated and can improve bronchial dysplasia in high-risk smokers, potentially preventing the progression to squamous cell carcinoma. The study is ongoing, and mutational load analyses are being conducted.

Asset Subtitle

Hui Yu

Meta Tag

Speaker Hui Yu

Topic Risk Factors, Risk Reduction & Tobacco Control

Keywords

Nivolumab

Bronchial Dysplasia

High-risk Smokers

Lung Squamous Cell Carcinoma

Immune Checkpoint Inhibitors

Bronchoscopy

Histologic Score

Immune Microenvironment

Mutational Load

Ongoing Study